Dasatinib
- BNF:
- 8.1.5
- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- January 2017
Comments
RED:
- NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia. (Decision date - January 2017).
- NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia. (Decision date - January 2017).
DO NOT PRESCRIBE (DNP):
- NICE TA714: treating Philadelphia-chromosome-positive acute
lymphoblastic leukaemia. (Terminated appraisal). (Decision date - August 2021).
Black Drug Classifications
- 6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again